Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Receivables (2020 - 2025)

Historic Receivables for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $27.7 million.

  • Burning Rock Biotech's Receivables rose 534.39% to $27.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.7 million, marking a year-over-year increase of 534.39%. This contributed to the annual value of $29.0 million for FY2024, which is 3766.14% up from last year.
  • Per Burning Rock Biotech's latest filing, its Receivables stood at $27.7 million for Q3 2025, which was up 534.39% from $28.6 million recorded in Q2 2025.
  • In the past 5 years, Burning Rock Biotech's Receivables ranged from a high of $29.0 million in Q4 2024 and a low of $4.5 million during Q2 2022
  • Moreover, its 5-year median value for Receivables was $23.3 million (2022), whereas its average is $21.8 million.
  • Per our database at Business Quant, Burning Rock Biotech's Receivables plummeted by 6278.61% in 2022 and then skyrocketed by 51891.65% in 2023.
  • Burning Rock Biotech's Receivables (Quarter) stood at $21.1 million in 2021, then rose by 4.15% to $22.0 million in 2022, then fell by 4.2% to $21.1 million in 2023, then soared by 37.66% to $29.0 million in 2024, then dropped by 4.66% to $27.7 million in 2025.
  • Its last three reported values are $27.7 million in Q3 2025, $28.6 million for Q2 2025, and $24.3 million during Q1 2025.